Lazy at 02:46, 24 February 2025

2025-02-24T02:46:11Z

← Older revision		Revision as of 19:46, 23 February 2025
Line 16:		Line 16:
	Glioblastoma is a highly aggressive cancer with poor prognosis, and metabolic approaches like the COC Protocol offer a novel angle by targeting cancer’s energy production and survival mechanisms. While it has shown promise in retrospective analyses, ongoing research is required to establish its efficacy through clinical trials.		Glioblastoma is a highly aggressive cancer with poor prognosis, and metabolic approaches like the COC Protocol offer a novel angle by targeting cancer’s energy production and survival mechanisms. While it has shown promise in retrospective analyses, ongoing research is required to establish its efficacy through clinical trials.

	\|treatment_category=Repurposed ~~Drug Combination~~		\|treatment_category=Repurposed Drugs
	\|links=* [Care Oncology Clinic official site](https://www.careoncology.com/)		\|links=* [Care Oncology Clinic official site](https://www.careoncology.com/)
	* [ClinicalTrials.gov studies related to metabolic therapy in glioblastoma](https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=metabolic+therapy&cntry=&state=&city=&dist=)		* [ClinicalTrials.gov studies related to metabolic therapy in glioblastoma](https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=metabolic+therapy&cntry=&state=&city=&dist=)

Lazy: Created page with " {{TreatmentInfo |drug_name=COC Protocol (Care Oncology Clinic Protocol) |FDA_approval=No (Individual drugs are FDA-approved for other conditions; the combination is not FDA-approved for cancer treatment) |used_for=Adjunctive metabolic therapy for glioblastoma and other cancers |clinical_trial_phase=Clinical use with retrospective analysis; some components in clinical trials for cancer |clinical_trial_explanation=The COC Protocol is being evaluated for its impact on canc..."

2025-02-24T02:45:32Z

Created page with " {{TreatmentInfo |drug_name=COC Protocol (Care Oncology Clinic Protocol) |FDA_approval=No (Individual drugs are FDA-approved for other conditions; the combination is not FDA-approved for cancer treatment) |used_for=Adjunctive metabolic therapy for glioblastoma and other cancers |clinical_trial_phase=Clinical use with retrospective analysis; some components in clinical trials for cancer |clinical_trial_explanation=The COC Protocol is being evaluated for its impact on canc..."

New page

{{TreatmentInfo
|drug_name=COC Protocol (Care Oncology Clinic Protocol)
|FDA_approval=No (Individual drugs are FDA-approved for other conditions; the combination is not FDA-approved for cancer treatment)
|used_for=Adjunctive metabolic therapy for glioblastoma and other cancers
|clinical_trial_phase=Clinical use with retrospective analysis; some components in clinical trials for cancer
|clinical_trial_explanation=The COC Protocol is being evaluated for its impact on cancer progression, particularly in glioblastoma. Retrospective studies suggest potential survival benefits, and individual drugs within the protocol have been studied for their anti-cancer effects.
|common_side_effects=Varies by drug; includes gastrointestinal upset, fatigue, liver enzyme changes, and potential interactions with other treatments
|OS_with=Some retrospective analyses indicate extended survival in glioblastoma patients using COC Protocol alongside standard treatments.
|PFS_with=Preliminary data suggests a potential role in slowing glioblastoma progression, but more studies are needed.
|usefulness_rating=4.5
|usefulness_explanation=The COC Protocol targets cancer metabolism through a multi-drug regimen, aiming to enhance standard treatments and reduce recurrence. Retrospective analyses suggest improved outcomes in glioblastoma patients, but randomized clinical trials are needed for definitive proof.
|toxicity_level=3
|notes=The COC Protocol is a metabolic-based treatment strategy designed to target multiple cancer pathways using repurposed drugs. It typically includes Metformin, Atorvastatin, Doxycycline, and Mebendazole, each chosen for its ability to disrupt cancer metabolism and inhibit tumor growth.

Glioblastoma is a highly aggressive cancer with poor prognosis, and metabolic approaches like the COC Protocol offer a novel angle by targeting cancer’s energy production and survival mechanisms. While it has shown promise in retrospective analyses, ongoing research is required to establish its efficacy through clinical trials.

|treatment_category=Repurposed Drug Combination
|links=* [Care Oncology Clinic official site](https://www.careoncology.com/)
* [ClinicalTrials.gov studies related to metabolic therapy in glioblastoma](https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=metabolic+therapy&cntry=&state=&city=&dist=)
* [Study on the role of metabolic interventions in glioblastoma](https://www.ncbi.nlm.nih.gov/pubmed/)
* [Metabolic targeting in glioblastoma: Review of repurposed drugs](https://www.mdpi.com/journal/pharmaceuticals)
|toxicity_explanation=Each drug in the protocol has an established safety profile, but the combination requires careful monitoring for potential interactions, liver function impact, and side effects. Coordination with an oncologist is advised to minimize risks.
|overview=The COC Protocol is an adjunctive metabolic therapy that combines four repurposed drugs to target glioblastoma’s metabolic vulnerabilities. Retrospective studies suggest potential survival benefits, but more clinical research is needed to confirm its efficacy and optimize its use alongside conventional treatments.
}}

COC protocol - Revision history

Lazy at 02:46, 24 February 2025